1-9 of 9
Frank Breitenbuecher
Close
Sort by
Journal Articles

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

Clinical Trials & Observations
Sabine Kayser, Richard F. Schlenk, Martina Correa Londono, Frank Breitenbuecher, Kerstin Wittke, Juan Du, Silja Groner, Daniela Späth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Thomas Fischer, Konstanze Döhner, for the German-Austrian AML Study Group (AMLSG)
Journal: Blood
Blood (2009) 114 (12): 2386–2392.
https://doi.org/10.1182/blood-2009-03-209999
Published: 2009
Journal Articles

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

Frank Breitenbuecher, Boyka Markova, Stefan Kasper, Birgit Carius, Torsten Stauder, Frank D. Böhmer, Kristina Masson, Lars Rönnstrand, Christoph Huber, Thomas Kindler, Thomas Fischer
Journal: Blood
Blood (2009) 113 (17): 4063–4073.
https://doi.org/10.1182/blood-2007-11-126664
Published: 2009
Includes: Supplemental data
Journal Articles

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

Brief Report
Frank Breitenbuecher, Susanne Schnittger, Rebekka Grundler, Boyka Markova, Birgit Carius, Alexandra Brecht, Justus Duyster, Torsten Haferlach, Christoph Huber, Thomas Fischer
Journal: Blood
Blood (2009) 113 (17): 4074–4077.
https://doi.org/10.1182/blood-2007-11-125476
Published: 2009
Journal Articles

The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.

Daniel B. Lipka, MD, Linda S. Hoffmann, MSc, Florian Heidel, MD, Boyka Markova, PhD, Stefan Kasper, MD, Frank Breitenbuecher, PhD, Thomas Kindler, MD, Ross Levine, MD, Joseph Elliot, PhD, Christoph Huber, MD, Thomas Fischer, MD
Journal: Blood
Blood (2007) 110 (11): 3544.
https://doi.org/10.1182/blood.V110.11.3544.3544
Published: 2007
Journal Articles

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

Clinical Trials & Observations
Florian Heidel, Fian K. Solem, Frank Breitenbuecher, Daniel B. Lipka, Stefan Kasper, M. H. Thiede, Christian Brandts, Hubert Serve, Johannes Roesel, Francis Giles, Eric Feldman, Gerhard Ehninger, Gary J. Schiller, Stephen Nimer, Richard M. Stone, Yanfeng Wang, Thomas Kindler, Pamela S. Cohen, Christoph Huber, Thomas Fischer
Journal: Blood
Blood (2006) 107 (1): 293–300.
https://doi.org/10.1182/blood-2005-06-2469
Published: 2006
Journal Articles

LS104, a Novel Kinase Inhibitor, Induces Apoptosis, Synergizes with Cytostatic Drugs and Is Targeting the Receptor Tyrosine Kinase FLT3.

Stefan Kasper, Thomas Kindler, MD, Florian Heidel, MD, Frank Breitenbuecher, PhD, Yvette Hoehn, MD, Daniel Lipka, Helmut Thomas, PhD, Christoph Huber, MD, Thomas Fischer, MD
Journal: Blood
Blood (2005) 106 (11): 3362.
https://doi.org/10.1182/blood.V106.11.3362.3362
Published: 2005
Journal Articles

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, Eli Estey, Francis Giles, Eric Feldman, Gerhard Ehninger, Gary Schiller, Virginia Klimek, Stephen D. Nimer, Alois Gratwohl, Chuna Ram Choudhary, Constan Mueller-Tidow, Hubert Serve, Harald Gschaidmeier, Pamela S. Cohen, Christoph Huber, Thomas Fischer
Journal: Blood
Blood (2005) 105 (1): 335–340.
https://doi.org/10.1182/blood-2004-02-0660
Published: 2005
Journal Articles

Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia

Clinical Trials & Observations
Thomas Kindler, Frank Breitenbuecher, Andreas Marx, Joachim Beck, Georg Hess, Birgit Weinkauf, Justus Duyster, Christian Peschel, Charles J. Kirkpatrick, Matthias Theobald, Harald Gschaidmeier, Christoph Huber, Thomas Fischer
Journal: Blood
Blood (2004) 103 (10): 3644–3654.
https://doi.org/10.1182/blood-2003-06-2071
Published: 2004
Journal Articles

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML

Clinical Trials & Observations Brief Report
Thomas Kindler, Frank Breitenbuecher, Andreas Marx, Georg Hess, Harald Gschaidmeier, Heinold Gamm, Charles J. Kirkpatrick, Christoph Huber, Thomas Fischer
Journal: Blood
Blood (2003) 101 (8): 2960–2962.
https://doi.org/10.1182/blood-2002-05-1469
Published: 2003